We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




First-Ever POC Analyzer Reads Patient's Immune System to Detect Diseases Before Symptoms Present

By LabMedica International staff writers
Posted on 19 May 2023
Print article
Image: The Immune Reveal point-of-care system goes beyond routine lab tests (Photo courtesy of Immune IQ)
Image: The Immune Reveal point-of-care system goes beyond routine lab tests (Photo courtesy of Immune IQ)

Each year, sepsis affects over 50 million individuals worldwide and accounts for nearly 20% of all fatalities. Additionally, sepsis poses a substantial economic strain, with projected costs exceeding USD 62 billion annually in the U.S. alone. However, rapid diagnosis and treatment could potentially prevent up to 80% of sepsis-related deaths. Now, a breakthrough point-of-care diagnostic platform that leverages the power of the human immune system is poised to address the two main challenges associated with sepsis: broad screening and rapid identification.

Immune Reveal, a first-of-its-kind point-of-care diagnostic platform, is a collaborative creation of Immune IQ (Twin Cities, MN, USA) and Honeywell (Charlotte, NC, USA). This groundbreaking platform integrates automatic disease screening with confirmatory tests to rapidly offer unique insights into various diseases, such as sepsis, heart disease, cancer, and COVID-19. The Immune Reveal platform offers diagnostic information quicker and more cost-effectively than ever before. With one of the most powerful data sets in the industry and the incorporation of artificial intelligence within its system, Immune Reveal could redefine the standard of care in diagnosis and treatment.

Immune Reveal generates one of the industry's most powerful data sets, which, when translated by artificial intelligence, can " read " diseases that a patient's immune system has detected even before the appearance of symptoms. This game-changing approach paves the way for a new era of integrated tests that can perform disease screening, confirmation testing, and precision treatment testing in minutes using the same card and sample. Immune IQ plans to commercialize sepsis detection as the initial test on the Immune Reveal platform. A recent clinical study successfully showcased Immune Reveal's ability to consistently generate a large cellular dataset. The combination of this data has been independently demonstrated in peer-reviewed publications to yield highly accurate sepsis detection.

"The human immune system is widely recognized as a near-perfect tool for detecting disease, even far in advance of noticeable symptoms. Immune Reveal is the first platform that can both read and decode the immune system's data in as soon as five minutes," said Immune IQ founder and CEO, David Deetz.

Related Links:
Immune IQ
Honeywell

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.